Therapy for Extrapulmonary Sarcoidosis

Robert P. Baughman; Elyse E. Lower

doi:10.1055/s-2002-36522

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2002; 23(6): 589-596
DOI: 10.1055/s-2002-36522

Therapy for Extrapulmonary Sarcoidosis

Robert P. Baughman, Elyse E. Lower

Interstitial Lung Disease and Sarcoidosis Clinic, Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio

Abstract

ABSTRACT

The treatment of extrapulmonary sarcoidosis has to be adapted to the various organs involved. No treatment is necessary for most asymptomatic individuals. In some cases, topical therapy is sufficient to control problems, especially skin and eye involvement. Systemic therapy usually starts with corticosteroids. However, for chronic forms of the disease, steroid sparing alternatives such as methotrexate and hydroxychloroquine are useful. In some neurologic and cardiac cases, the response to corticosteroids is limited. In that case, alternatives are sought for these refractory patients. Drugs that inhibit tumor necrosis factor may prove useful in these patients. Among the new anti-tumor necrosis factor drugs are thalidomide and infliximab, an antibody to tumor necrosis factor.

KEYWORD

Methotrexate - hydroxychloroquine - azathioprine - infliximab - thalidomide - tumor necrosis factor - prednisone

Full Text

References

REFERENCES

1 Hunninghake G W, Costabel U, Ando M. ATS/ERS/ WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis . 1999; 16 149-173
2 Baughman R P, Lower E E. Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis . 1997; 14 121-130
3 Zeitlin J F, Tami T A, Baughman R, Winget D. Nasal and sinus manifestations of sarcoidosis. Am J Rhinol . 2000; 14 157-161
4 Lower E E, Broderick J P, Brott T G, Baughman R P. Diagnosis and management of neurologic sarcoidosis. Arch Intern Med . 1997; 157 1864-1868
5 Mana J, Gomez Vaquero C, Montero A. Lofgren's syndrome revisited: a study of 186 patients. Am J Med . 1999; 107 240-245
6 James D G, Sharma O P. Parotid gland sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis . 2000; 17 27-32
7 Engasser P G, Maibach H I. Cosmetic and dermatology: bleaching creams. J Am Acad Dermatol . 1981; 5 143-147
8 Controlled evaluation of loteprendnol etabonate and prednisolone acetate in the treatment of acute anterior uveitis: loteprednol etabonate US uveitis study. Am J Ophthalmol . 1999; 127 597-599
9 Francois J, Victoria-Troncoso V. Corticosteroid glaucoma. Ophthalmologica . 1977; 174 195-209
10 Jonas J B, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol . 2001; 132 425-427
11 Gelwan M J, Kellen R I, Burde R M, Kupersmith M J. Sarcoidosis of the anterior visual pathway: successes and failures. J Neurol Neurosurg Psychiatry . 1988; 51 1473-1480
12 Agbogu B N, Stern B J, Sewell C, Yang G. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol . 1995; 52 875-879
13 Hunninghake G W, Gilbert S, Pueringer R. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med . 1994; 149 893-898
14 Gottlieb J E, Israel H L, Steiner R M, Triolo J, Patrick H. Outcome in sarcoidosis: the relationship of relapse to corticosteroid therapy. Chest . 1997; 111 623-631
15 Rizzato G, Montemurro L, Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis . 1998; 15 52-58
16 Baughman R P, Shipley R, Eisentrout C E. Predictive value of gallium scan, angiotensin-converting enzyme level, and bronchoalveolar lavage in two-year follow-up of pulmonary sarcoidosis. Lung . 1987; 165 371-377
17 Neville E, Walker A N, James D G. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med . 1983; 208 525-533
18 Rizzato G, Fraioli P, Montemurro L. Nephrolithiasis as a presenting feature of chronic sarcoidosis. Thorax . 1995; 50 555-559
19 Siltzbach L E, Teirstein A S. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand . 1964; 425(suppl) 302S-308S
20 Jones E, Cagen J P. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. Am Acad Dermatol . 1990; 23 487-490
21 Henderson C A, Ilchyshyn A, Curry A R. Laryngeal and cutaneous sarcoidosis treated with methotrexate. J R Soc Med . 1994; 87 632-633
22 Rajendran R, Theertham M, Salgia R, Muthuswamy P. Methotrexate in the treatment of cutaneous sarcoidosis. Sarcoidosis . 1994; 11(suppl) S335-S338
23 Veien N K, Brodthagen H. Cutaneous sarcoidosis treated with methotrexate. Br J Dermatol . 1977; 97 213-216
24 Webster G F, Razsi L K, Sanchez M, Shupack J L. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol . 1991; 24 451-454
25 Lower E E, Baughman R P. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med . 1995; 155 846-851
26 Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol . 1995; 32 866-869
27 Lee J B, Koblenzer P S. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Dermatol . 1998; 39 835-838
28 Krzystolik M, Power W J, Foster C S. Diagnostic and therapeutic challenges of sarcoidosis. International Ophthalmology Clinics . 1998; 38 61-76
29 Van Gelder N R, Kaplan H J. Immunosuppression in uveitis therapy. Springer Seminars in Immunopathology . 1999; 21 179-190
30 Dev S, McCallum R M, Jaffe G J. Methotrexate for sarcoid-associated panuveitis. Opthalmology . 1999; 106 111-118
31 Baughman R P, Lower E E, Bradley D A, Kaufman A H. Use of cytotoxic therapy for chronic opthalmic sarcoidosis. Sarcoidosis Vasc Diff Lung Dis . 1999; 16(suppl) S17
32 Samson C M, Waheed N, Baltatzis S, Foster C S. Methotrexate therapy for chronic nonifectious uveitis: analysis of a case series of 160 patients. Ophthalmology . 2001; 108 1134-1139
33 Gedalia A, Molina J F, Ellis G S, Galen W, Moore C, Espinoza L R. Low-dose methotrexate therapy for childhood sarcoidosis. J Pediatr . 1997; 130 25-29
34 Lennarson P, Barney N P. Interstitial keratitis as presenting ophthalmic sign of sarcoidosis in a child. J Pediatr Ophthalmol Strabismus . 1996; 32 194-196
35 Shetty A K, Zganjar B E, Ellis Jr S G, Ludwig I H, Gedalia A. Low-dose methotrexate in the treatment of severe juvenile rheumatoid arthritis and sarcoid iritis. J Pediatr Ophthalmol Strabismus . 1999; 36 125-128
36 Kaye O, Palazzo E, Grossin M, Bourgeois P, Kahn M F, Malaise M G. Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis. Br J Rheumatol . 1995; 34 642-644
37 Rizzato G, Montemurro L, James D G. Sarcoidosis and other granulomatous disorders. New York: Marcel Dekker 1994
38 James D G, Carstairs L S, Trowell J, Sharma O P. Treatment of sarcoidosis: report of a controlled therapeutic trial. Lancet . 1967; 2 526-528
39 Oksanen V. Neurosarcoidosis: clinical presentations and course in 50 patients. Acta Neurol Scand . 1986; 73 283-290
40 Sharma O P. Neurosarcoidosis: a personal perspective based on the study of 37 patients. Chest . 1997; 112 220-228
41 James D G. Differential diagnosis of facial nerve palsy. Sarcoidosis . 1997; 14 115-120
42 Hunninghake G W, Costabel U, Ando M. ATS/ERS/ WASOG statement on sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis . 1999; 16 149-173
43 O'Brien G M, Baughman R P, Broderick J P, Arnold L, Lower E E. Paranoid psychosis due to neurosarcoidosis. Sarcoidosis . 1994; 11 34-36
44 Sharma O P. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurologic involvement. Arch Neurol . 1998; 55 1248-1254
45 Martinet Y, Pinkston P, Saltini C, Spurzem J, Muller-Quernheim J, Crystal R G. Evaluation of the in vitro and in vivo effects of cyclosporine on the lung T-lymphocyte alveolitis of active pulmonary sarcoidosis. Am Rev Respir Dis . 1996; 138 1242-1248
46 Wyser C P, van Schalkwyk M E, Alheit B, Bardin P G, Joubert J R. Treatment of progressive pulmonary sarcoidosis with cyclosporin A: a randomized controlled trial. Am J Respir Crit Care Med . 1997; 156 1571-1576
47 Stern B J, Schonfeld S A, Sewell C, Krumholz A, Scott P, Belendiuk G. The treatment of neurosarcoidosis with cyclosporine. Arch Neurol . 1992; 49 1065-1072
48 Zuber M, Defer G, Cesaro P, Degos J D. Efficacy of cyclophosphamide in sarcoid radiculomyelitis. J Neurol Neurosurg Psychiatry . 1992; 55 166-167
49 Bullmann C, Faust M, Hoffmann A. Five cases with central diabetes insipidus and hypogonadism as first presentation of neurosarcoidosis. Eur J Endocrinol . 2000; 142 365-372
50 Zajicek J P, Scolding N J, Foster O. Central nervous system sarcoidosis: diagnosis and management. QJM . 1999; 92 103-117
51 Kang S, Suh J H. Radiation therapy for neurosarcoidosis: report of three cases from a single institution. Radiation Oncol Invest . 1999; 7 309-312
52 Yoshida T, Tanaka M, Okamoto K, Hirai S. Neurosarcoidosis following augmentation mammoplasty with silicone. Neurol Res . 1996; 18 319-320
53 Nakagawa K, Tago M, Terahara A. A single institutional outcome analysis of Gamma Knife radiosurgery for single or multiple brain metastases. Clin Neurol Neurosurg . 2000; 102 227-232
54 Vigliani M C, Duyckaerts C, Hauw J J, Poisson M, Magdelenat H, Delattre J Y. Dementia following treatment of brain tumors with radiotherapy administered alone or in combination with nitrosourea-based chemotherapy: a clinical and pathological study. J Neuro-oncol . 1999; 41 137-149
55 Baughman R P, Winget D B, Bowen E H, Lower E E. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis . 1997; 14 154-158
56 Suzuki T, Kanda T, Kubota S, Imai S, Murata K. Holter monitoring as a noninvasive indicator of cardiac involvement in sarcoidosis. Chest . 1994; 106 1021-1024
57 Paz H L, McCormick D J, Kutalek S P, Patchefsky A. The automated implantable cardiac defibrillator: prophylaxis in cardiac sarcoidosis. Chest . 1994; 106 1603-1607
58 DeRemee R A. The present status of therapy of pulmonary sarcoidosis: a house divided. Chest . 1977; 71 388-393
59 Rizzato G, Fraioli P, Montemurro L. Long-term therapy with deflazacort in chronic sarcoidosis. Chest . 1991; 99 301-309
60 Montemurro L, Schiraldi G, Fraioli P, Tosi G, Riboldi A, Rizzato G. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int . 1991; 49 71-76
61 Gonnelli S, Rottoli P, Cepollaro C. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int . 1997; 61 382-385
62 Rizzato G, Montemurro L. Reversibility of exogenous corticosteroid-induced bone loss. Eur Respir J . 1993; 6 116-119
63 Lacher M J. Spontaneous remission response to methotrexate in sarcoidosis. Ann Intern Med . 1968; 69 1247-1248
64 Lower E E, Baughman R P. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci . 1990; 299 153-157
65 Baughman R P, Lower E E. A clinical approach to the use of methotrexate for sarcoidosis. Thorax . 1999; 54 742-746
66 Morgan S L, Baggott J E, Vaughn W H. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. Ann Intern Med . 1994; 121 833-841
67 Baughman R P, Winget D B, Lower E E. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis . 2000; 17 60-66
68 Fries J F, Ramey D R, Singh G. Suggested guidelines for monitoring liver toxicity in rheumatoid arthritis patients with methotrexate: comment on the article by Kremer et al. Arthritis Rheum . 1994; 37 1829-1830
69 Hassan W. Methotrexate and liver toxicity: role of surveillance liver biopsy: conflict between guidelines for rheumatologists and dermatologists. Ann Rheum Dis . 1996; 55 273-275
70 Kremer J M, Alarcon G S, Lightfoot Jr W R. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum . 1994; 37 316-328
71 Baughman R P, Weber F L, Bejarano P B, Koehler A, Lower E E. Methotrexate for chronic sarcoidosis: hepatotoxicity assessed by liver biopsy. Am J Respir Crit Care Med . 1999; 159 A342
72 White D A, Rankin J A, Stover D E, Gellene R A, Gupta S. Methotrexate pneumonitis: bronchoalveolar lavage findings suggest an immunologic disorder. Am Rev Respir Dis . 1989; 139 18-21
73 Grierson D J. Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. Ann Rheum Dis . 1997; 56 188-190
74 Jones S K. Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol . 1999; 140 3-7
75 Mazzuca S A, Yung R, Brandt K D, Yee R D, Katz B P. Current practices for monitoring ocular toxicity related to hydroxychloroquine (Plaquenil) therapy. J Rheumatol . 1994; 21 59-63
76 Ben Ari Z, Mehta A, Lennard L, Burroughs A K. Azathioprine-induced myelosuppression due to methyltransferase defiency in a patient with autoimmune hepatitis. J Hepatology . 1995; 23 351-354
77 Escousse A, Mousson C, Santona L. Azathioprine-induced pancytopenia in homogenous thioprine methyltransferase-deficient renal transplant recipeints: a family study. Transplant Proc . 1995; 27 1739-1742
78 Fries J F, Williams C A, Ramey D, Bloch D A. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum . 1993; 36 297-306
79 Ritters B, Grabensee B, Heering P. Malignancy under immunosuppressive therapy including cyclosporin. Transplant Proc . 1994; 26 2656-2657
80 Taylor A E, Shuster S. Skin cancer after renal transplant: the causal role of azathioprine. Acta Dermatology and Venereology . 1992; 72 115-119
81 McGeown M G, Douglas J F, Middleton D. One thousand renal transplants at Belfast City Hospital: post-graft neoplasia 1968-1999, comparing azathioprine only with cyclosporin-based regimes in a single centre. Clin Transpl . 2000; 16 193-202
82 Singh G, Fries J F, Williams C A, Zatarain E, Spitz P, Bloch D A. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol . 1991; 18 188-194
83 Lamers C B, Griffioen G, Van Hogezand A R, Veenendaal R A. Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease. Scand J Gastroenterol . 1999; 230(suppl) 111-115
84 Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology . 1996; 46 1607-1612
85 Zisman D A, Lynch J P, Toews G B, Kazerooni E A, Flint A, Martinez F J. Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids. Chest . 2000; 117 1619-1626
86 Baughman R P, Lower E E. Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest . 1992; 102 1090-1094
87 Talar-Williams C, Hijazi Y M, Walther M M. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med . 1996; 124 477-484
88 Schoenike S E. Ifosfamide and mesna. Clin Pharmacol . 1990; 9 179-191
89 Lower E E, Blau R, Gazder P, Tummala R. The risk of premature menopause induced by chemotherapy for early breast cancer. J Womens Health Gend Based Med . 1999; 8 949-954
90 Strieter R M, Remick D G, Ward P A. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun . 1988; 155 1230-1236
91 Marques L J, Zheng L, Poulakis N, Guzman J, Costabel U. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med . 1999; 159 508-511
92 Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med . 1997; 155 1665-1669
93 Sheskin J. Thalidomide in the treatment of lepra reaction. Clin Pharmacol Ther . 1965; 6 303
94 Jacobson J M, Greenspan J S, Spritzler J. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med . 1997; 336 1487-1493
95 Singhal S, Mehta J, Desikan R. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med . 1999; 341 1565-1571
96 Rousseau L, Beylot-Barry M, Doutre M S, Beylot C. Cutaneous sarcoidosis successfully treated with low doses of thalidomide. Arch Dermatol . 1998; 134 1045-1046
97 Baughman R P, Judson M A, Teirstein A S, Moller D R, Lower E E. Thalidomide for chronic sarcoidosis. Chest . 2002; 122 227-232
98 Marriott J B, Cookson S, Carlin E. A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines. AIDS Res Human Retroviruses . 1997; 13 1625-1631
99 Gerr F E, Letz R. Reliability of a widely used test of peripheral cutaneous vibration sensitivity and a comparison of two testing protocols. Brit J Industrial Med . 1988; 45 635-639
100 Hamuryudan V, Mat C, Saip S. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. Ann Intern Med . 1998; 128 443-450
101 Kavanaugh A, Clair E W, McCune W J, Braakman T, Lipsky P. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol . 2000; 27 841-850
102 Maini R, St Clair W E, Breedveld F. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet . 1999; 354 1932-1939
103 Lofberg R. Treatment of fistulas in Crohn's disease with infliximab. Gut . 1999; 45 642-643
104 Chaudhari U, Romano P, Mulcahy L D, Dooley L T, Baker D G, Gottlieb A B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet . 2001; 357 1842-1847
105 Oh C J, Das K M, Gottlieb A B. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol . 2000; 42 829-830
106 Sfikakis P P, Theodossiadis P G, Katsiari C G, Kaklamanis P, Markomichelakis N N. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet . 2001; 358 295-296
107 Baughman R P, Lower E E. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis . 2001; 18 70-74
108 Yee A MF, Pochapin M B. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis-alpha therapy. Ann Intern Med . 2001; 135 27-31
109 Alabi O F, Lower E E, Baughman R P. Use of infliximab in refractory sarcoidosis. Am J Respir Crit Care Med . 2001; 163 A557
110 Schaible T F. Long term safety of infliximab. Can J Gastroenterol . 2000; 14 (suppl C) 29C-32C
111 Charles P J, Smeenk R J, De Jong J, Feldmann M, Maini R N. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis and Rheumatism . 2000; 43 2383-2390
112 Kean J, Gershon S, Wise R P. Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent. N Engl J Med . 2001; 345 1098-1104